ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,04315
0,00%
Bitcoin
98.611,95
0,87%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Ocean Biomedical Inc (OCEA)

  7. Ocean Biomedical Inc (OCEA) News

OCEA

Ocean Biomedical (OCEA)

Ocean Biomedical Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OCEA
DatumZeitQuelleÜberschriftSymbolFirma
22/11/202422h45GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
22/10/202422h45GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination LetterNASDAQ:OCEAOcean Biomedical Inc
01/10/202414h01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling ResponsesNASDAQ:OCEAOcean Biomedical Inc
27/08/202414h01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention PlatformsNASDAQ:OCEAOcean Biomedical Inc
23/08/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
23/08/202422h30GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
23/07/202423h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
05/06/202413h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024NASDAQ:OCEAOcean Biomedical Inc
30/05/202413h44GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
16/05/202414h01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe DiseaseNASDAQ:OCEAOcean Biomedical Inc
24/04/202422h51GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KNASDAQ:OCEAOcean Biomedical Inc
28/03/202413h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASLNASDAQ:OCEAOcean Biomedical Inc
08/03/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
04/03/202423h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
29/02/202414h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver MeetingNASDAQ:OCEAOcean Biomedical Inc
14/02/202400h43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCEAOcean Biomedical Inc
19/01/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
17/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
05/12/202314h15GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 AntibodyNASDAQ:OCEAOcean Biomedical Inc
29/11/202323h41GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
15/11/202312h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
15/11/202312h20Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:OCEAOcean Biomedical Inc
14/11/202314h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
26/10/202311h30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
26/10/202311h30PR Newswire (US)Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
24/10/202312h30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan KurtisNASDAQ:OCEAOcean Biomedical Inc
17/10/202314h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
12/10/202323h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
12/10/202314h01PR Newswire (US)Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwideNASDAQ:OCEAOcean Biomedical Inc
12/10/202314h01GlobeNewswire Inc.Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients WorldwideNASDAQ:OCEAOcean Biomedical Inc
 Showing the most relevant articles for your search:NASDAQ:OCEA

Kürzlich von Ihnen besucht

TG
DTE
Deutsche Telekom
TG
ALV
Allianz
DBI
SDXP
SDAX
NASDAQ
TSLA
Tesla
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
USOTC
BASFY
BASF (QX)
NASDAQ
NVDA
NVIDIA
TG
432
Arbor Metals
TG
RHM
Rheinmetall
USOTC
RHHBY
Roche (QX)
AMEX
XLF
Financial Select Sector
COIN
SOLUSD
Solana
NASDAQ
AAPL
Apple
USOTC
ADDYY
Adidas (QX)
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten